Arcus Biosciences Inc (NYSE:RCUS) CEO Terry J. Rosen bought 41,540 shares of the stock in a transaction on Tuesday, June 4th. The shares were acquired at an average cost of $7.91 per share, with a total value of $328,581.40. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
RCUS traded up $0.22 during trading on Friday, hitting $7.95. The company had a trading volume of 1,008,200 shares, compared to its average volume of 144,574. The stock has a market capitalization of $324.66 million, a P/E ratio of -5.56 and a beta of 1.22. Arcus Biosciences Inc has a one year low of $7.15 and a one year high of $16.06. The stock has a 50-day moving average of $8.95.
Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.07). The company had revenue of $1.75 million during the quarter, compared to the consensus estimate of $1.25 million. Arcus Biosciences had a negative net margin of 613.46% and a negative return on equity of 22.72%. As a group, research analysts predict that Arcus Biosciences Inc will post -1.64 EPS for the current year.
A number of equities analysts have recently weighed in on RCUS shares. Zacks Investment Research raised shares of Arcus Biosciences from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Thursday, March 7th. BTIG Research started coverage on shares of Arcus Biosciences in a research report on Monday, March 18th. They set a “buy” rating and a $20.00 price target on the stock. Svb Leerink reissued an “outperform” rating on shares of Arcus Biosciences in a research report on Friday, May 3rd. Finally, Citigroup reissued a “buy” rating and set a $25.00 price target on shares of Arcus Biosciences in a research report on Friday, May 24th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $17.50.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Featured Story: Understanding Average Daily Trade Volume
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.